IL-37 and inflammation in multiple sclerosis
IL-37: a novel regulator of inflammation in CNS autoimmunity
This research looks at whether a natural protein called IL‑37 can calm harmful inflammation and support repair in people with multiple sclerosis (MS).
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11324171 on NIH RePORTER |
What this research studies
Researchers will compare immune cells from people with MS and healthy volunteers to see which cells make IL‑37 receptor and how they respond to IL‑37. Adult participants may be asked to give blood samples and medical history so lab tests can measure immune responses. The team will use lab models, including organotypic brain/spinal cord slice cultures and animal models, to see if IL‑37 reduces inflammatory actions of monocytes and Th1/Th17 cells and promotes repair signals such as amphiregulin. Findings will guide whether IL‑37 could be developed into treatments that both limit inflammation and help tissue recover.
Who could benefit from this research
Good fit: Adults (21+) with a diagnosis of multiple sclerosis who can provide blood samples and clinical information are the most likely candidates to participate.
Not a fit: People under 21, those without MS, or anyone seeking an immediate new therapy are unlikely to receive direct benefit from this primarily lab-focused research.
Why it matters
Potential benefit: If successful, this work could point to new, safer treatments that reduce MS inflammation and help repair damaged nerve coverings.
How similar studies have performed: Preclinical work on IL‑37 and other anti-inflammatory cytokines shows promise for lowering inflammation, but IL‑37-based approaches are relatively new and have not yet been widely tested in patients.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Rostami, A.m. — Thomas Jefferson University
- Study coordinator: Rostami, A.m.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.